Diligence memo · auto-generated · as of July 2, 2026
BioIntelliSense, Inc.
BioIntelliSense, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
BioIntelliSense, Inc. operates in Other Health Care, based in GOLDEN.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
BioIntelliSense, Inc. has raised $140M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $58M on 2025-12-04.
Most recent recorded round closed around 2025-12-04.
Valuation (modeled)modeled
Provath models BioIntelliSense, Inc. at approximately $329M (range $211M–$411M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.45× the median modeled value of Series C Other Health Care companies in 2025–2027 (20 peers) — value vs value, same stage and era. Within the normal band (145% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 28 months.
Last raise 7 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 1.3× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 97% of Other Health Care peers (5377 compared).
Modeled value ranks above 91% of those peers.
Closest niche peers: RESTOR3D, Inc., ByHeart, Inc., SpyGlassPharma, Inc., VantAI Holdings, Inc., ObjectiveHealth, Inc..
Peoplefiled
15 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.